leisure time -WSS

leisure time

author：explore 2025-10-01 00:05:31 - browse：1

Is Wegovy the future of cardiology? Can Novo Nordisk ever make enough of it? And will there ever be an Apple of pharma?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. In the wake of a massively important clinical trial of Novo Nordisk’s obesity drug Wegovy, our colleague Elaine Chen joins us to explain what we know and don’t know about data that could change the practice of medicine. Then, Mizuho Securities biotech strategist Jared Holz calls in to discuss whether explosive popularity of obesity treatments could help create the first trillion-dollar drug company.

For more on what we cover, here’s the news on the Wegovy study; here’s more on its implications; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Ahead of JPM, here's who's profiting most in health care

WSS

Charles Manson follower Leslie Van Houten released from prison after 53 years

Retired US general questions alleged Putin, Prigozhin meeting

Iowa House, Senate pass 6

AdventHealth escalates lawsuit against insurance vendor Multiplan

UCB departs biotech trade group BIO

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

hotspot

leisure time

explore

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Federal weight loss drug coverage is 30 years out of date

At least 13 dead in Texas as scorching temps continue

Palantir health business leans on meeting customers’ needs

Trump demands the U.S. pay no more for drugs than other countries … again

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

Supreme Court strikes down use of affirmative action

3 trends to watch in health tech's hiring outlook for 2024

Medicare details structure of new drug price negotiation program

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

focus

Bulgari apologizes to China for listing Taiwan as a country after online backlash

California’s proposed $25 per hour health care minimum wage

UCB departs biotech trade group BIO

Federal weight loss drug coverage is 30 years out of date

J&J to buy cancer drug developer Ambrx Biopharma

Morgan Health, with ambitious aims, wants you to know it’s still here

focus

hotspot

explore

explore